Thomas Weiss

Faculty, Professor (Associate)

University Hospital Regensburg

Germany

Research Interests

Explore related searches

Professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Thomas Weiss is an Associate Professor at University Hospital Regensburg in Germany. His research focuses on liver diseases, particularly the roles of various proteins and signaling pathways in conditions such as hypercholesterinemia, hepatitis, and liver fibrosis. Recent articles authored by Professor Weiss explore the molecular mechanisms underlying liver dysfunction and the potential therapeutic targets for hepatocellular carcinoma and metabolic-associated liver diseases.

Articles (17)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

University of Hohenheim

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Thomas Weiss

Research Interests

Explore related searches

Contact this professor

About

Articles (17)

Proprotein Convertase Subtilisin/Kexin Type 9 Induction in Hypercholesterinemic Patients With Primary and Metastatic Liver Tumors

Hepatic Amyloid Beta-42-Metabolizing Proteins in Liver Steatosis and Metabolic Dysfunction-Associated Steatohepatitis

Role of WISP1 in Stellate Cell Migration and Liver Fibrosis

Hepatic Bone Morphogenetic Protein and Activin Membrane-Bound Inhibitor Levels Decline in Hepatitis C but Are Not Associated with Progression of Hepatocellular Carcinoma

Consequences of Amyloid-β Deficiency for the Liver

The TGF- β1 target WISP1 is highly expressed in liver cirrhosis and cirrhotic HCC microenvironment and involved in pro- and anti-tumorigenic effects

Saturated Fat-Mediated Upregulation of IL-32 and CCL20 in Hepatocytes Contributes to Higher Expression of These Fibrosis-Driving Molecules in MASLD

Interleukin-1ß Attenuates Expression of Augmenter of Liver Regeneration (ALR) by Regulating HNF4α Independent of c-Jun

Gas6 in chronic liver disease-a novel blood-based biomarker for liver fibrosis

Preclinical Efficacy and Toxicity Analysis of the Pan-Histone Deacetylase Inhibitor Gossypol for the Therapy of Colorectal Cancer or Hepatocellular Carcinoma

Preclinical Efficacy and Toxicity Analysis of the Pan-Histone Deacetylase Inhibitor Gossypol for the Therapy of Colorectal Cancer or Hepatocellular Carcinoma

Chemerin Overexpression in the Liver Protects against Inflammation in Experimental Non-Alcoholic Steatohepatitis

Chemerin Overexpression in the Liver Protects against Inflammation in Experimental Non-Alcoholic Steatohepatitis

Hepatocyte expressed chemerin-156 does not protect from experimental non-alcoholic steatohepatitis

Toxicogenomics directory of chemically exposed human hepatocytes (vol 88, pg 2261, 2014)

Serum Amyloid Beta42 Is Not Eliminated by the Cirrhotic Liver: A Pilot Study

Serum Amyloid Beta42 Is Not Eliminated by the Cirrhotic Liver: A Pilot Study

Collaborators (8)

Maiju Myllys

Olga Renner

Lusine Danielyan

Stephan C. Bischoff

Steven Dooley

Sascha Venturelli

Christa Buechler

Christian Leischner

Make your next move.